Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

Kenji Tamura; Kazuhiko Nakagawa; Takayasu Kurata; Taroh Satoh; Toshiji Nogami; Koji Takeda; Shigeki Mitsuoka; Naruo Yoshimura; Shinzoh Kudoh; Shunichi Negoro; Masahiro Fukuoka

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

【24h】

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

机译：TZT-1027（一种新型合成的dolastatin 10衍生物和微管蛋白聚合抑制剂）的I期研究在3周的课程中的第1天和第8天施用于患有晚期实体瘤的患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of TZT-1027 (soblidotin), a dolastatin 10 analogue, in Japanese patients with advanced solid tumors when administered on days 1 and 8 in 3-week courses.

机译：在日本患有晚期实体瘤的日本患者中，在第3天的第1天和第8天给药时，要确定其对dolastatin 10类似物的最大耐受剂量（MTD），剂量限制毒性（DLT）和TZT-1027（索必利汀）的药代动力学每周课程。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2007年第2期|285-293|共9页
作者
Kenji Tamura; Kazuhiko Nakagawa; Takayasu Kurata; Taroh Satoh; Toshiji Nogami; Koji Takeda; Shigeki Mitsuoka; Naruo Yoshimura; Shinzoh Kudoh; Shunichi Negoro; Masahiro Fukuoka;
展开▼
作者单位

Department of Medical Oncology Kinki University School of Medicine Osaka Japan;

Department of Medical Oncology Kinki University School of Medicine Osaka Japan;

Department of Medical Oncology Kinki University School of Medicine Osaka Japan;

Department of Medical Oncology Kinki University School of Medicine Osaka Japan;

Department of Medical Oncology Kinki University School of Medicine Osaka Japan;

Department of Clinical Oncology Osaka City General Hospital Osaka Japan;

Department of Respiratory Medicine Osaka City University Medical School Osaka Japan;

Department of Respiratory Medicine Osaka City University Medical School Osaka Japan;

Department of Respiratory Medicine Osaka City University Medical School Osaka Japan;

Department of Clinical Oncology Osaka City General Hospital Osaka Japan;

Department of Medical Oncology Kinki University School of Medicine Osaka Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Dolastatin; TZT-1027; Phase I; Antitubulin; Solid tumors;

机译：Dolastatin;TZT-1027;I期;抗微管蛋白;实体瘤;

相似文献

外文文献
中文文献
专利

1. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks [J] . Nobuyuki Yamamoto, Masahiro Andoh, Masaaki Kawahara Cancer science. . 2009,第2期

机译：TZT-1027是一种新型合成的dolastatin 10衍生物和微管蛋白聚合抑制剂的I期研究，每周向晚期实体瘤患者提供3周
2. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. [J] . Schoffski P, Thate B, Beutel G, Annals of oncology: official journal of the European Society for Medical Oncology . 2004,第4期

机译：TZT-1027（一种新型合成的dolastatin 10衍生物）的I期和药代动力学研究，每3周一次向晚期难治性癌症患者静脉输注1小时。
3. A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors [J] . Claire F. Verschraegen, Harry Raftopoulos, Kevie Feit, The Internet Journal of Oncology . 2007,第1期

机译：每三周第1天和第8天对患有晚期或转移性实体瘤的患者进行TZT-1027（索必利汀）和吉西他滨联合治疗的I期研究
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors [O] . Roger B. Cohen, Suzanne F. Jones, Charu Aggarwal, -1

机译：DANUSERTIB（PHA-739358）的I次升级研究在晚期固体肿瘤患者的14天循环中施用为24小时输注和没有G-CSF
6. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks [O] . Nobuyuki Yamamoto, Masahiro Andoh, Masaaki Kawahara, 2009

机译：TZT-1027的I阶段研究，一种新型合成的少剂素10衍生物和小管蛋白聚合抑制剂，每周给晚期固体瘤患者3周

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

摘要

著录项

相似文献

相关主题

期刊订阅